Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Pharming (PHAR) Cost of Revenue (2020 - 2025)

Historic Cost of Revenue for Pharming (PHAR) over the last 6 years, with Q3 2025 value amounting to -$443000.0.

  • Pharming's Cost of Revenue fell 10154.43% to -$443000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $218.5 million, marking a year-over-year decrease of 1121.75%. This contributed to the annual value of $35.4 million for FY2024, which is 4040.54% up from last year.
  • Per Pharming's latest filing, its Cost of Revenue stood at -$443000.0 for Q3 2025, which was down 10154.43% from $65.6 million recorded in Q2 2025.
  • In the past 5 years, Pharming's Cost of Revenue registered a high of $14.8 billion during Q1 2021, and its lowest value of -$14.8 billion during Q2 2021.
  • Over the past 5 years, Pharming's median Cost of Revenue value was $28.7 million (recorded in 2024), while the average stood at $34.7 million.
  • Per our database at Business Quant, Pharming's Cost of Revenue skyrocketed by 99230.43% in 2023 and then plummeted by 10154.43% in 2025.
  • Quarter analysis of 5 years shows Pharming's Cost of Revenue stood at -$41.8 million in 2021, then surged by 142.07% to $17.6 million in 2022, then surged by 604.82% to $124.0 million in 2023, then fell by 4.23% to $118.8 million in 2024, then plummeted by 100.37% to -$443000.0 in 2025.
  • Its Cost of Revenue stands at -$443000.0 for Q3 2025, versus $65.6 million for Q2 2025 and $34.6 million for Q1 2025.